[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-control-subjects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-control-subjects":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100658601","understanding-lifespan-trajectories-of-social-cognition-brain-microstructure-and-iron-dysregulation-in-schizophrenia-100658601",false,"NCT07856381","Understanding Lifespan Trajectories of Social Cognition, Brain Microstructure and Iron Dysregulation in Schizophrenia","SilverMinds - Lifespan Trajectories of Social Cognition and Iron Dysregulation in Schizophrenia","Inclusion criteria (all participants):\n\nage 18-70 years at baseline; normal or corrected-to-normal vision; sufficient hearing; fluency in German; willingness and ability to understand and comply with study procedures. Participants must either be healthy adults without any mental health disorder (HC) or have a confirmed DSM-5 diagnosis of SZ.\n\nInclusion criteria (SZ only):\n\nclinical stability at assessment, defined as no clinically significant change in psychopathological symptoms and no modification of pharmacotherapy for at least three months prior to study entry, as confirmed by the treating psychiatrist; full remission is not required.\n\nExclusion criteria (all participants):\n\nincapacity to consent; current or lifetime history of brain surgery or epilepsy; MRI contraindications (unremovable metal parts in the upper body, active implants, claustrophobia); current or past substance abuse disorder (excluding caffeine and nicotine); pregnancy.\n\nExclusion criteria (HC only):\n\nany current or lifetime Axis I psychiatric disorder; first-degree relative with an Axis I disorder; any neurological disorder or other mental health condition; current or past use of psychotropic medication.\n\nAdditional Eligibility Criteria for Cycle-Timed Neuroimaging:\n\nTo minimize hormonal confounding of emotion-regulation-related neural measures, menstruating female participants will be scanned in the early follicular phase (cycle days 1-6), requiring regular menstrual cycles (21-35 days) and a negative pregnancy test at relevant visits.\n\nUse of hormonal contraception will be recorded.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},180,"ESTIMATED","OBSERVATIONAL","This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time.\n\nTwo groups will take part in the study:\n\n1. people diagnosed with schizophrenia\n2. healthy adults without schizophrenia\n\nParticipants in both groups will complete a series of behavioral tasks and questionnaires. These will assess abilities such as understanding other people, processing social information, and regulating emotions. For participants with schizophrenia, we will also assess clinical symptoms and their severity.\n\nThe study includes three assessment visits:\n\n1. Baseline: at the beginning of the study\n2. 12-month follow-up: approximately one year later\n3. 24-month follow-up: approximately two years later\n\nAt all three visits, participants will complete behavioral tests and questionnaires, and blood and hair samples will be collected. These samples may help researchers investigate biological factors that are related to mental health, stress, and changes over time.\n\nParticipants will also undergo an MRI brain scan at the baseline visit and again at the 12-month follow-up.\n\nPeople with schizophrenia may experience changes in thinking, emotions, social functioning, physical health, and brain function across adulthood. However, we still do not fully understand how these changes develop over time or how they differ from normal aging.\n\nBy comparing people with schizophrenia with healthy adults of different ages and following them over time, we can study possible differences in aging trajectories. This means examining whether certain abilities, symptoms, biological markers, or brain characteristics change differently with age in people with schizophrenia.\n\nThe study uses an accelerated longitudinal design. Instead of following one group of people for many decades, researchers recruit participants from different age groups and follow them for a shorter period. Combining information across these age groups can help researchers estimate longer-term patterns of change.",[26,27],"Healthy Control Subjects","Schizophrenia Diagnosis",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"schizophrenia","social cognition","Brain iron","accelerated longitudinal design","age trajectory","lifespan","Cognitive Dysfunction","Longitudinal Studies","Magnetic Resonance Imaging","Quantitative Susceptibility Mapping","Extracellular Vesicles","Oxidative Stress","Redox Regulation","Glutathione","Hair Proteomics","Psychosocial Functioning","Negative Symptoms","Theory of Mind","Emotion Recognition","Emotion Regulation","Attributional Style","NDEV","functional outcome","RECRUITING","2026-09-23",{"date":55,"type":56},"2026-10-02","ACTUAL",{"date":58,"type":56},"2026-09-01",{"date":60,"type":22},"2030-09-30",{"name":62,"class":63},"Medical University Innsbruck","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":64},"100656879","phase-2-this-protocol-is-a-sub-study-under-the-ppmi-program-it-is-a-longitudinal-single-center-study-to-assess-the-performance-of-18fav-133-imaging-using-high-and-standard-resolution-pet-in-individuals-enrolled-with-parkinsons-disease-pd-for-up-to-12-months-100656879","NCT07830654","This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.","A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F]AV- 133 in Parkinson's Disease [Dual PET AV-133 in PD]","Inclusion Criteria:\n\n1. Participants over the age of 18 who are enrolled in the PPMI Clinical protocol with a diagnosis of Parkinson's disease (PD) or Healthy Control participants enrolled in the PPMI Clinical protocol.\n2. Able to provide informed consent.\n3. Male or Female (females must meet additional criteria specified below as applicable)\n\n   1. Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]AV-133\n\n      * Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n      * Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n   2. Females of childbearing potential must not be pregnant, breastfeeding or lactating.\n\n      * Includes a negative urine pregnancy test prior to injection of \\[18F\\]AV-133 on day of PET scan.\n\nExclusion Criteria:\n\n1. Received any of the following medications that might interfere with \\[18F\\]AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Baseline \\[18F\\]AV-133 injection.\n2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.",{"count":73,"type":22},50,"INTERVENTIONAL",[76],"PHASE2","The study is a longitudinal, single-center study to assess progression of \\[18F\\]AV-133 imaging in PD participants. Participants will be followed for up to 12 months. Approximately 45 PD participants and 5 healthy control participants will be recruited from the ongoing PPMI Clinical 002 study. Participants will be comprehensively assessed at Baseline and follow up according to the Schedule of Activities. Participants will undergo PET imaging assessments with \\[18F\\]AV-133. After tracer injection, participants will be imaged on PET cameras at each imaging timepoint-one with the NX camera and one with a standard PET camera-in accordance with the Image Acquisition Protocol (IAP).",[79,26],"Parkinson's Disease (PD)","2026-09-15",{"date":82,"type":56},"2026-09-21",{"date":84,"type":56},"2025-09-25",{"date":86,"type":22},"2027-09",{"name":88,"class":63},"Michael J. Fox Foundation for Parkinson's Research"]